Keyphrases
PORTEC
100%
Endometrial Cancer
100%
Adjuvant Therapy
100%
Integrated Risk
71%
Risk Profile
71%
Brachytherapy
57%
Vaginal Brachytherapy
53%
Molecular Profile
50%
Randomized Trial
50%
Quality Assurance
50%
Intermediate Risk
50%
Dummy Run
25%
Protocol Compliance
25%
Mean Dose
16%
Vaginal Recurrence
14%
Recurrence-free Survival
14%
Accruals
14%
Stage IB
14%
Lymphovascular Invasion
14%
Health Care Costs
14%
Local Control
14%
In Situ
8%
Quality Assurance Procedures
8%
Quality Assurance Program
8%
Computed Tomography
8%
Undertreatment
7%
Radiotherapy
7%
Local Recurrence
7%
Overtreatment
7%
International Federations
7%
Randomized Phase III Trial
7%
Cancer-related
7%
Pathological Diagnosis
7%
Total Abdominal Hysterectomy
7%
Patient-reported Symptoms
7%
Inclusion-exclusion
7%
Patient Risk
7%
Tumor Characteristics
7%
Laparoscopic Hysterectomy
7%
Obstetrics
7%
Recurrence Risk
7%
Distant Recurrence
7%
Salpingo-oophorectomy
7%
Exclusion Criteria
7%
Quality of Life Impact
7%
Adverse Events
7%
Pelvic Recurrence
7%
Overall Survival
7%
Endometrioid Endometrial Cancer
7%
After Surgery
7%
Medicine and Dentistry
Adjuvant Therapy
100%
Endometrial Cancer
100%
Brachytherapy
91%
Recurrent Disease
33%
Protocol Compliance
16%
Quality of Life
16%
Pelvis
16%
Recurrence Free Survival
16%
Arm
16%
Health Care Cost
16%
Neoplasm
8%
Adverse Event
8%
Hysterectomy
8%
Histology
8%
Gynecology
8%
Radiation Therapy
8%
Overall Survival
8%
Obstetrics
8%
Side Effect
8%
Symptom
8%
Salpingooophorectomy
8%
Checklist
5%
